L & S Advisors Inc Vertex Pharmaceuticals Inc Transaction History

L & S Advisors Inc

$771 Million
Q2 2024

A detailed history of L & S Advisors Inc transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, L & S Advisors Inc holds 3,482 shares of VRTX stock, worth $1.75 Million. This represents 0.21% of its overall portfolio holdings.

Number of Shares

3,482

Previous 3,309 5.23%

Holding current value

$1.75 Million

Previous $1.38 Million 18.0%

% of portfolio

0.21%

Previous 0.18%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$392.81 - $485.53 $67,956 - $83,996	173 Added 5.23%	3,482 $1.63 Million
Q1 2024 May 10, 2024	BUY	$407.69 - $446.08 $49,738 - $54,421	122 Added 3.83%	3,309 $1.38 Million
Q4 2023 Feb 13, 2024	SELL	$343.0 - $410.68 $374,213 - $448,051	-1,091 Reduced 25.5%	3,187 $1.3 Million
Q3 2023 Nov 13, 2023	BUY	$338.18 - $362.46 $320,256 - $343,249	947 Added 28.43%	4,278 $1.49 Million
Q2 2023 Aug 11, 2023	BUY	$314.42 - $351.91 $242,732 - $271,674	772 Added 30.17%	3,331 $1.17 Million
Q1 2023 May 10, 2023	SELL	$283.23 - $323.1 $173,903 - $198,383	-614 Reduced 19.35%	2,559 $806,000
Q4 2022 Feb 13, 2023	BUY	$285.76 - $321.48 $906,716 - $1.02 Million	3,173 New	3,173 $916,000
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $938,790 - $1.25 Million	-4,535 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$255.65 - $303.1 $149,810 - $177,616	586 Added 14.84%	4,535 $1.23 Million
Q2 2020 Aug 13, 2020	SELL	$225.48 - $295.8 $52,311 - $68,625	-232 Reduced 5.55%	3,949 $1.15 Million
Q1 2020 May 13, 2020	BUY	$199.77 - $247.81 $275,882 - $342,225	1,381 Added 49.32%	4,181 $995,000
Q4 2019 Feb 13, 2020	BUY	$166.71 - $223.91 $466,788 - $626,948	2,800 New	2,800 $613,000

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of L & S Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on L & S Advisors Inc with notifications on news.

Account